MX2022009353A - Metodo de optimizacion estructural para mejorar el rendimiento teranostico de la terapia con radionuclidos dirigida a receptores de peptidos para el cancer. - Google Patents

Metodo de optimizacion estructural para mejorar el rendimiento teranostico de la terapia con radionuclidos dirigida a receptores de peptidos para el cancer.

Info

Publication number
MX2022009353A
MX2022009353A MX2022009353A MX2022009353A MX2022009353A MX 2022009353 A MX2022009353 A MX 2022009353A MX 2022009353 A MX2022009353 A MX 2022009353A MX 2022009353 A MX2022009353 A MX 2022009353A MX 2022009353 A MX2022009353 A MX 2022009353A
Authority
MX
Mexico
Prior art keywords
theranostic
cancers
performance
improve
optimization method
Prior art date
Application number
MX2022009353A
Other languages
English (en)
Inventor
Dongyoul Lee
Michael K Schultz
Mengshi Li
Nicholas Baumhover
F Christopher Pigge
Original Assignee
Univ Iowa Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Iowa Res Found filed Critical Univ Iowa Res Found
Publication of MX2022009353A publication Critical patent/MX2022009353A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1036—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona en determinadas modalidades un conjugado dirigido al carcinoma que comprende la Fórmula I donde T es un ligando dirigido a SST2R, L es un enlazador, y X es un quelante, para el tratamiento terapéutico del cáncer, y métodos para su uso.
MX2022009353A 2020-01-29 2021-01-28 Metodo de optimizacion estructural para mejorar el rendimiento teranostico de la terapia con radionuclidos dirigida a receptores de peptidos para el cancer. MX2022009353A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967497P 2020-01-29 2020-01-29
PCT/US2021/015389 WO2021154921A1 (en) 2020-01-29 2021-01-28 Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers

Publications (1)

Publication Number Publication Date
MX2022009353A true MX2022009353A (es) 2022-09-02

Family

ID=74669566

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009353A MX2022009353A (es) 2020-01-29 2021-01-28 Metodo de optimizacion estructural para mejorar el rendimiento teranostico de la terapia con radionuclidos dirigida a receptores de peptidos para el cancer.

Country Status (10)

Country Link
US (1) US20230105344A1 (es)
EP (1) EP4096723A1 (es)
JP (1) JP2023512660A (es)
KR (1) KR20220132556A (es)
CN (1) CN115087467A (es)
AU (1) AU2021212741A1 (es)
BR (1) BR112022014006A2 (es)
CA (1) CA3166142A1 (es)
MX (1) MX2022009353A (es)
WO (1) WO2021154921A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS64815B1 (sr) * 2017-01-12 2023-12-29 Radiomedix Inc Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4282439A1 (en) 2022-05-23 2023-11-29 Erasmus University Rotterdam Medical Center Radioisotope labeled sstr2-agonists with linkers
US20240254106A1 (en) * 2022-12-13 2024-08-01 Crinetics Pharmaceuticals, Inc. Somatostatin subtype-2 receptor (sst2r) targeted therapeutics and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044625T2 (hu) * 2011-08-31 2019-11-28 Somscan Aps PET nyomjelzõ neuroendokrin tumorok képalkotásához
CN106084005B (zh) * 2016-06-15 2020-02-14 广州军区广州总医院 靶向生长抑素受体的Al18F-NOTA-PEG6-TATE及其制备方法和应用
RS64815B1 (sr) * 2017-01-12 2023-12-29 Radiomedix Inc Lečenje ćelija kancera koje prekomerno eksprimiraju receptore za somatostatin primenom derivata oktreotida heliranih sa radioizotopima
AU2019287595A1 (en) * 2018-04-27 2020-12-03 University Of Iowa Research Foundation Compositions for chelating metals at low temperatures

Also Published As

Publication number Publication date
JP2023512660A (ja) 2023-03-28
BR112022014006A2 (pt) 2022-10-11
CA3166142A1 (en) 2021-08-05
AU2021212741A1 (en) 2022-07-28
EP4096723A1 (en) 2022-12-07
CN115087467A (zh) 2022-09-20
KR20220132556A (ko) 2022-09-30
US20230105344A1 (en) 2023-04-06
WO2021154921A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MX2022009353A (es) Metodo de optimizacion estructural para mejorar el rendimiento teranostico de la terapia con radionuclidos dirigida a receptores de peptidos para el cancer.
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
MY197235A (en) Derivatives of amanita toxins and their conjugation to a cell binding molecule
MX2021015887A (es) Un conjugado de un agente citotóxico y una molécula de unión a células con enlazadores ramificados.
MX2021009147A (es) Un conjugado de un analogo de amatoxina con enlazadores ramificados.
NZ602084A (en) Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
HK1073601A1 (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
MX353964B (es) Agentes terapeuticos y usos de los mismos.
MX2022008605A (es) Quelatos macrociclicos y sus usos.
MX2009011320A (es) Terapia anticancer enzimatica.
AU2002352187A8 (en) Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
EP1583564A4 (en) IMPROVED LINKERS FOR RADIO-PHARMACEUTICAL COMPOUNDS
MX2015006931A (es) Terapia combinada para tratar cánceres her2-positivos.
MX2023010512A (es) Agentes de union multiespecificos contra cd40 y cd137 en terapia.
MX2023005192A (es) Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
EE200300467A (et) Liposoomide suunamine maatriksi metalloproteinaaside inhibiitorite abil
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
MX2022014886A (es) Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
TW200724158A (en) Combination therapy in the treatment of cancer
MX2022014223A (es) Terapia de combinacion para amiloidosis de la ttr.
AU2001272017A1 (en) Targeted combination immunotherapy of cancer and infectious diseases
MX2022003044A (es) Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer.
MX2023007436A (es) Arn terapeutico para tratar cancer.
WO2021222595A3 (en) Multispecific antibodies targeting cd38 and epcam and uses thereof